Acromegaly

Overview

Acromegaly is a rare, long-term hormonal disorder in which the body makes too much growth hormone (GH), usually because of a noncancerous growth hormone-secreting tumor in the pituitary gland at the base of the brain. Excess GH raises insulin-like growth factor 1 (IGF-1), a hormone that drives enlargement of the hands, feet, facial bones, organs, and soft tissues. It is most often diagnosed in adults and can cause sleep apnea, diabetes, high blood pressure, heart disease, arthritis, headaches, and vision problems. Untreated disease can shorten life expectancy, whereas successful treatment can substantially improve symptoms and may restore life expectancy toward normal. NIDDK acromegaly overview

The present standard of care is to remove the causative pituitary tumor through transsphenoidal surgery—typically performed through the nose—when feasible. Persistent or recurrent disease is managed with drugs that suppress GH release, block GH action, or, in selected cases, radiotherapy; treatment success is assessed mainly by age-adjusted IGF-1, GH testing, symptoms, and pituitary MRI. Experts use the term remission rather than an absolute cure when no active disease can be detected after treatment, because biochemical recurrence remains possible. Diagnosis and treatment update 2024 remission consensus

Scope of Recent Research (2020–present)

Research activity has been steady and clinically meaningful, but most recent work is aimed at achieving reliable lifelong biochemical control, reducing treatment burden, improving surgical precision, and matching therapy to tumor biology—not at genetically correcting or permanently eliminating every tumor cell. The clearest curative route remains complete tumor removal, sometimes supplemented by radiotherapy; no gene therapy, gene-editing, cell therapy, or RNA therapy has yet demonstrated a clinical cure for acromegaly. Current development is therefore best characterized as progress toward more effective and convenient disease control rather than a near-term universal cure. 2025 therapeutic-outcomes consensus Investigational-drugs review

Major Breakthroughs and Emerging Therapies

The most important cure-oriented clinical strategy remains better local control of the GH-secreting pituitary tumor. Modern endoscopic transsphenoidal surgery, specialized pituitary surgical teams, improved imaging, and repeat surgery can produce drug-free remission in appropriately located tumors. For residual tumor that cannot safely be removed, stereotactic radiosurgery focuses radiation on the adenoma and can induce delayed endocrine remission, although it is not an immediate cure and requires long-term hormone follow-up. Surgical and multimodal management review Radiosurgery meta-analysis

The largest recent pharmacologic advance is paltusotine, marketed in the United States as Palsonify. It is a once-daily oral small molecule that activates somatostatin receptor subtype 2, thereby reducing GH secretion from many pituitary tumors. The FDA approved it on September 25, 2025 for adults whose disease has not responded adequately to surgery or for whom surgery is not an option. This improves access to effective medical control without regular depot injections, but it does not remove the adenoma and should not be described as curative. FDA approval announcement FDA prescribing information

A second emerging strategy blocks GH after it has been released rather than trying to stop its secretion. ALXN2420, formerly AZP-3813, is a compact 16-amino-acid growth hormone receptor antagonist designed for daily subcutaneous administration alongside a somatostatin analog. In laboratory receptor studies and juvenile-rat experiments, ALXN2420 inhibited GH-receptor signaling and produced additive IGF-1 lowering when combined with octreotide. This approach could help people whose hormone levels remain high despite tumor-directed medication, but it is a systemic control strategy rather than a tumor-eradicating therapy. ALXN2420 preclinical study

At the discovery level, researchers are increasingly treating acromegaly as a biologically diverse group of pituitary neuroendocrine tumors, often called PitNETs. Spatial transcriptomics and single-cell RNA sequencing—methods that measure gene activity in individual cells while preserving information about where those cells sit in a tumor—have identified distinct tumor regions and candidate progression-associated genes, including DLK1 and RCN1, as well as altered transforming growth factor-beta signaling. These observations may eventually support personalized drugs that directly inhibit tumor growth, but they are not yet validated treatment targets in patients. Spatial and single-cell mapping study

Clinical Trials and Experimental Approaches

Crinetics Pharmaceuticals’ phase 3 PATHFNDR program established paltusotine as the major recent clinical advance. In one 24-week randomized, double-blind trial of 111 adults with uncontrolled acromegaly, 56% of people receiving paltusotine achieved normal IGF-1 compared with 5% receiving placebo. In a separate 36-week trial of 58 people previously controlled on injectable therapy, 83% who switched to paltusotine maintained biochemical control compared with 4% receiving placebo. These results supported U.S. approval, but the endpoint was biochemical control during treatment, not durable remission after stopping treatment. FDA approval announcement

Alexion Pharmaceuticals, part of AstraZeneca Rare Disease, is sponsoring ASTERIA, a recruiting phase 2 randomized, double-blind, placebo-controlled trial of ALXN2420 added to somatostatin analog therapy in adults whose acromegaly remains inadequately controlled. Its primary aim is to test whether 15 weeks of combination treatment lowers IGF-1 more effectively than placebo plus standard therapy. Earlier phase 1 testing in 101 healthy volunteers found dose-related IGF-1 reductions and no major safety signal over short-term dosing, but it did not test clinical efficacy in people with acromegaly. ASTERIA trial record ALXN2420 phase 1 study

Methodologies and Scientific Approaches

Clinical studies use normalized IGF-1 as the central biomarker because it integrates overall GH activity more reliably than a single GH measurement. Researchers pair serial hormone measurements with symptom assessments and MRI scans of residual or recurrent tumor; oral glucose suppression testing can provide additional confirmation when diagnosis or remission status is uncertain. 2024 remission consensus

Preclinical work combines receptor-binding and cell-signaling assays with animal studies to test whether candidate drugs suppress the GH–IGF-1 pathway safely and add to existing somatostatin analogs. In parallel, surgical tumor samples are being studied with single-cell and spatial genomic platforms to identify cell subtypes, tumor microenvironments, molecular predictors of drug response, and targets that might make future treatment tumor-destructive rather than merely hormone-suppressive. ALXN2420 preclinical study Spatial and single-cell mapping study

Leading Institutions and Funding

Crinetics Pharmaceuticals led the paltusotine development program, while the phase 3 studies enrolled patients across 73 sites in 18 countries, illustrating the multinational collaboration required for a rare disease. Alexion Pharmaceuticals is leading the current ALXN2420 phase 2 program. These industry programs are the most visible recent investments in new acromegaly medicines, though their goal remains chronic control rather than surgical replacement or genetic cure. FDA drug-trials snapshot ASTERIA trial record

In the United States, the National Institute of Diabetes and Digestive and Kidney Diseases supports broader endocrine and hypothalamic-pituitary research through its Endocrinology and Hormone Signaling program and conducts clinical investigation of acromegaly and related metabolic disorders through NIH programs. Publicly identifiable disease-specific cure funding amounts were not consistently reported in the sources reviewed, so the most defensible description is programmatic rather than a single dollar figure. NIDDK Endocrinology and Hormone Signaling program NIDDK endocrine fellowship specialties

Strengths, Limitations, and Challenges

The field’s main strength is that several complementary options can now be combined: expert surgery can remove the source of disease, somatostatin-directed drugs can suppress tumor hormone secretion, GH-receptor antagonists can lower downstream IGF-1, and radiosurgery can treat selected residual tumors. Paltusotine is a practical advance because it offers oral treatment and produced strong phase 3 biochemical-control results. However, it still requires ongoing use and carries class-related risks including gallstones, altered blood sugar, slowed heart rate, thyroid abnormalities, fat malabsorption, and vitamin B12 changes. FDA approval announcement

The central limitation is biological and anatomical: invasive pituitary tumors may wrap around structures that cannot be safely resected, while drugs that normalize IGF-1 may leave residual tumor in place. Radiosurgery can help achieve delayed remission, but a 2024 meta-analysis estimated new pituitary hormone deficiency after stereotactic radiosurgery at 23%, underscoring the trade-off between tumor control and preservation of normal pituitary function. Molecular studies also show substantial tumor heterogeneity, so a target discovered in one tumor subgroup may not work in another. Radiosurgery meta-analysis Spatial and single-cell mapping study

Outlook and Future Directions

As of September 7, 2026, acromegaly is not close to a universal biological cure, but cure-oriented progress is plausible through more complete and safer tumor removal, more accurate imaging and molecular prediction of surgical or drug response, and eventually therapies that selectively destroy GH-secreting PitNET cells. Near-term milestones to watch are durable real-world outcomes with oral paltusotine, ASTERIA phase 2 results for ALXN2420 in patients with uncontrolled disease, and validation of genomic targets such as DLK1, RCN1, and transforming growth factor-beta pathway components in functional tumor models. Until a tumor-eradicating targeted therapy reaches clinical trials, complete surgical remission will remain the most established path to a drug-free cure. ASTERIA trial record Spatial and single-cell mapping study 2025 therapeutic-outcomes consensus

References

• NIDDK acromegaly overview — National Institute of Diabetes and Digestive and Kidney Diseases, 2020.
• Diagnosis and treatment update — Ershadinia and Tritos, 2022.
• 2024 remission consensus — Giustina et al. and the Acromegaly Consensus Group, 2024.
• Surgical and multimodal management review — Koutourousiou et al., 2024.
• Radiosurgery meta-analysis — Albano et al., 2024.
• 2025 therapeutic-outcomes consensus — Giustina et al. and the Acromegaly Consensus Group, 2025.
• Investigational-drugs review — Pivonello et al., 2024.
• FDA approval announcement — U.S. Food and Drug Administration, 2025.
• FDA prescribing information — U.S. Food and Drug Administration, 2025.
• ALXN2420 preclinical study — Ravel et al., 2025.
• Spatial and single-cell mapping study — Liu et al., 2024.
• ASTERIA trial record — Alexion Pharmaceuticals and ClinicalTrials.gov, 2026.
• ALXN2420 phase 1 study — van der Lely et al., 2026.
• FDA drug-trials snapshot — U.S. Food and Drug Administration, 2025.
• NIDDK Endocrinology and Hormone Signaling program — National Institute of Diabetes and Digestive and Kidney Diseases, 2026.
• NIDDK endocrine fellowship specialties — National Institute of Diabetes and Digestive and Kidney Diseases, 2026.